Biomarkers of inflammation and coagulation predict non‐AIDS‐defining events in a prospective cohort of virologically suppressed people living with HIV

Documenti analoghi

• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  di: Inés Suárez‐García, et al.
  Pubblicazione: (2025)
• Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
  di: Pierluigi Francesco Salvo, et al.
  Pubblicazione: (2025)
• Long‐acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re‐suppression outcomes in virally suppressed individuals living with HIV
  di: Kyle Ring, et al.
  Pubblicazione: (2025)
• Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
  di: C. Piñeiro, et al.
  Pubblicazione: (2024)
• Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study
  di: Cristina Mussini, et al.
  Pubblicazione: (2026)